Goldman Sachs
SMMT icon

Goldman Sachs’s Summit Therapeutics SMMT Stock Holding History

Goldman Sachs’s Portfolio SMMT Stock Details SMMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$65.8M Buy
4,513,399
+4,202,671
+1,353% +$74.5M 0.01% 1572
2026
Q1 		$5.89M Sell
310,728
-174,838
-36% -$2.83M ﹤0.01% 3538
2025
Q4 		$8.49M Sell
485,566
-11,981
-2% -$225K ﹤0.01% 3256
2025
Q3 		$10.3M Buy
497,547
+194,121
+64% +$4.71M ﹤0.01% 2933
2025
Q2 		$6.46M Sell
303,426
-269,365
-47% -$6.14M ﹤0.01% 3170
2025
Q1 		$11M Sell
572,791
-337,211
-37% -$6.76M ﹤0.01% 2607
2024
Q4 		$16.2M Buy
910,002
+414,647
+84% +$8.04M ﹤0.01% 2335
2024
Q3 		$10.8M Buy
495,355
+41,411
+9% +$579K ﹤0.01% 2627
2024
Q2 		$3.54M Sell
453,944
-226,657
-33% -$1.22M ﹤0.01% 3476
2024
Q1 		$2.82M Buy
680,601
+486,193
+250% +$1.93M ﹤0.01% 3600
2023
Q4 		$507K Buy
194,408
+2,210
+1% +$4.55K ﹤0.01% 4748
2023
Q3 		$359K Sell
192,198
-158,804
-45% -$303K ﹤0.01% 4809
2023
Q2 		$881K Sell
351,002
-89,887
-20% -$164K ﹤0.01% 4437
2023
Q1 		$772K Buy
440,889
+385,378
+694% +$1.05M ﹤0.01% 4573
2022
Q4 		$236K Sell
55,511
-5,229
-9% -$9.51K ﹤0.01% 5243
2022
Q3 		$72K Buy
60,740
+26,347
+77% +$29.8K ﹤0.01% 5755
2022
Q2 		$34K Sell
34,393
-2,384
-6% -$3.34K ﹤0.01% 6098
2022
Q1 		$90K Sell
36,777
-10,313
-22% -$26K ﹤0.01% 6138
2021
Q4 		$126K Buy
47,090
+5,536
+13% +$26.6K ﹤0.01% 6069
2021
Q3 		$208K Buy
41,554
+865
+2% +$6.21K ﹤0.01% 5703
2021
Q2 		$304K Sell
40,689
-45,820
-53% -$301K ﹤0.01% 5519
2021
Q1 		$508K Buy
86,509
+51,700
+149% +$334K ﹤0.01% 5106
2020
Q4 		$164K Buy
+34,809
New +$147K ﹤0.01% 5160

Other funds holding SMMT

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Goldman Sachs's SMMT Position: Q2 2026 in Review

Goldman Sachs increased its Summit Therapeutics (SMMT) stake by 1,353% in Q2 2026, buying an estimated $74.5M and bringing the position to 4,513,399 shares worth $65.8M. The position accounts for 0.01% of the portfolio, ranked #1572.

Goldman Sachs first reported a position in SMMT in Q4 2020 and has held it in 23 quarters since. 242 funds tracked by Wall St. Rank hold SMMT as of Q2 2026.

  • Goldman Sachs held 4,513,399 shares of Summit Therapeutics worth $65.8M as of Q2 2026.
  • Goldman Sachs bought 4,202,671 Summit Therapeutics shares in Q2 2026, an estimated $74.5M.
  • Summit Therapeutics made up 0.01% of Goldman Sachs's portfolio in Q2 2026, its #1572 holding.
  • Goldman Sachs first reported a position in Summit Therapeutics in Q4 2020 and has held it in 23 quarters since.
  • 242 funds tracked by Wall St. Rank held Summit Therapeutics as of Q2 2026.

Based on Goldman Sachs's 13F filing for Q2 2026, filed 14 Aug 2026.